FBLG FibroBiologics, Inc.
FibroBiologics, Inc. (FBLG) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +95.8% since its last earnings release on July 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About FibroBiologics, Inc.
FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON.
Sector
Healthcare
Industry
Biotechnology